Physician profile
Cody Mcbride
NPI 1689038812
$4,999.82
in general payments reported to CMS, 2019-2025
39 companies · $775 in 2025
The $775 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,047 · 2022: $64.44 · 2023: $2,668 · 2024: $446 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632 · Travel and Lodging: $884 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.56 |
| Travel and Lodging | $883.74 |
| Education | $373.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,015.34 | 2023-2024 | Synchromedii, Intellis Adaptivestim, Accurian |
| Forte Bio-Pharma LLC | $361.71 | 2022-2023 | Prolate, Nalocet |
| Lilly USA, LLC | $350.15 | 2021-2025 | Verzenio, Retevmo |
| Relievant Medsystems, INC. | $151.22 | 2023 | Intracept |
| Merck Sharp & Dohme LLC | $143.62 | 2021-2025 | Keytruda, Lynparza |
| Si-Bone, INC. | $129.49 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.36 | 2021-2024 | Relistor |
| Novartis Pharmaceuticals Corporation | $119.77 | 2024-2025 | |
| Gilead Sciences, INC. | $107.19 | 2024-2025 | Trodelvy |
| Spinal Simplicity, LLC | $105.13 | 2023-2024 | Ha Minuteman G3-R |
| Astrazeneca Pharmaceuticals LP | $100.23 | 2024-2025 | Enhertu, Lynparza |
| Daiichi Sankyo INC. | $90.49 | 2024-2025 | Enhertu |
| Collegium Pharmaceutical, INC. | $83.25 | 2021-2023 | Belbuca |
| Orexo US, INC. | $81.96 | 2021 | |
| Amgen INC. | $80.79 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.